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InNigeria, one of the highest tuberculosis (TB) burdened nations, sputum smearmicroscopy is routinely employed for TB diagnosis
at Directly Observed Treatment Short-Course (DOTS) Centers. This diagnostic algorithm does not differentiate Mycobacterium
tuberculosis complex (MTC) from nontuberculous mycobacteria (NTM). Between December 2008 and January 2009, consecutive
patients diagnosed with TB were screened for inclusion at 10 DOTS centers in Ibadan, Nigeria. To verifyMycobacterium species in
patients diagnosed, we cultured and identified mycobacterial isolates using PCR, line probe assay, and spoligotyping techniques.
From 48 patients screened, 23 met the inclusion criteria for the study. All the 23 study patients had a positive culture. Overall, we
identified 11/23 patients (48%) with MTC only, 9/23 (39%) with NTM only, and 3/23 (13%) with evidence of both MTC and NTM.
Strains of MTC identified were Latin American Mediterranean (LAM) genotype (𝑛 = 12),M. africanum (𝑛 = 1), and the genotype
family T (𝑛 = 1). FourM. avium-intracellulare-M. scrofulaceum complexes, oneM. chelonae complex, oneM. abscessus, and oneM.
intracellulare were identified. Our findings underscore the need to incorporate molecular techniques for more precise diagnosis of
TB at DOTS centers to improve clinical outcomes and safe guard public health, particularly in TB endemic countries.
1. Introduction
For several years, Nigeria has remained in the league of the
highest TB burdened nations of the world and is currently
ranked 4th globally [1]. Sputum smear microscopy is rou-
tinely employed for TB diagnosis at Directly Observed
Treatment Short-Course (DOTS) Centers in Nigeria [2].
The diagnostic algorithm entails interpreting presence of
acid fast bacilli in sputum smear microscopy as TB. This
algorithm does not differentiate Mycobacterium tuberculosis
complex (MTC) from nontuberculous mycobacteria (NTM)
[3], which are ubiquitous environmental mycobacteria [4–6],
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Table 1: Epidemiological profile of patients with positive mycobacterial culture.
Number of patients Clinicalhistory
Ziehl-
Neelsen
staining
Culture on selective agar
MTC/NTM
(phenotypic speciation)
INNO-LiPA test
NTM (molecular
speciation)
Spoligotyping
MTC
(molecular
speciation)
Identity of
patients
10 New + M. tuberculosis NR + 1, 3, 4, 6, 7, 8,10, 12, 13, 14
1 Relapse + M. tuberculosis NR + 5
1 New + M. tuberculosisUnclassified NTM MAIS complex + 2
1 Relapse + M. tuberculosisUnclassified NTM
MAIS complex
M. intracellulare + 11
1 New + M. tuberculosisUnclassified NTM ND + 9
6 New + Unclassified NTM ND NR 15, 16, 17, 18,19, 21
1 New + Unclassified NTM
MAIS complex
M. chelonae
complex
NR 20
1 New + Unclassified NTM MAIS complexM. abscessus NR 22
1∗ Relapse − Unclassified NTM MAIS complex NR 23
∗ refers to patient with negative sputum smear but positive X-ray; +/− positive or negative; NR: not required; ND: not determined.
MAIS complex:Mycobacterium avium-intracellulare-Mycobacterium scrofulaceum complex.
increasingly isolated from immune competent and immune
compromised hosts [2, 7, 8]. Also other acid fast bacilli, like
Rhodococcus spp. cannot be identified using this approach.
Since clinical implications and therapeutic options for NTM
differ markedly from those for TB, accurate discrimination
of TB from NTM infection is essential to avoid under-
or overtreatment of either condition, bearing in mind the
potential patient care and economic consequences [6, 8].
To explore whether misdiagnosis is a problem in Nigeria,
we cultured sputum and conducted molecular characteriza-
tion of acid fast isolates in patients already diagnosed with
TB based on the local diagnostic algorithm at DOTS centers
in Ibadan, Southwestern Nigeria.
2. Materials and Methods
2.1. Patient Cohort. This study was conducted at 10 DOTS
centers in Ibadan, Southwestern Nigeria, between December
2008 and January 2009. Consecutive patients diagnosed
with TB (based on positive smear microscopy or symptoms
plus chest X-ray) were screened for inclusion. Those on TB
therapy for more than 3 days were excluded. Demographic,
clinical, and radiologic data of eligible participants were
extracted from medical records. Ethical clearance for the
studywas obtained fromOyo StateMinistry ofHealth Ethical
Review Board as part of an ongoing TB project.
2.2. Bacteria Culture and Morphological Identification. Spu-
tum sample from each patient was digested and decontamin-
ated with N-acetyl-L-cysteine, 4% NaOH; concentrated by
high speed centrifugation; stained with auramine-rhodamine;
and examined by fluorescent microscopy. Pellets from
each sample were cultured simultaneously on Mycobacteria
growth indicator (MGIT) tubes containing oleic acid-albu-
min-dextrose-catalase and polymyxin-amphotericin B-nali-
dixic acid-trimethoprim-azlocillin and Middlebrook 7H11
agar medium plates (for morphological identification). The
inoculated media were incubated at 37∘C with 7% CO
2
for
6 weeks as previously described [9]. Positive cultures were
screened byZiehl-Neelsen andGram stain in order to exclude
other positive Gram staining bacteria. Observation of colony
morphology, recognition of mixed infections (more than one
Mycobacterium species), and differentiation of the patients’
cultures into MTC and NTM was carried out through
microscopic examination of the growths on theMiddlebrook
7H11 culture plates [5].
2.3. Molecular Identification. Definitive molecular identifi-
cation for NTM was carried out using mainly the INNO-
LiPA assay (INNO-LiPA Mycobacteria v2; Innogenetics
N.V., Gent, Belgium) for the amplification of the 16S–23S
rRNA. Only five patients’ samples that were morphologically
identified as NTM were available for this. The spoligotyping
technique was carried out using a commercially available kit
(Spoligotyping Isogen Life Science, De Meern, Netherlands)
and this was used mainly for MTC (for all morphologically
identified MTC samples).
3. Results and Discussion
A total of 48 patients were screened for inclusion. Out of
these, 25 patients had received TB therapy for more than
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three days and were excluded. Thus, the study population
comprised 23 patients (3 diagnosed as TB relapse due to
prior full course of TB therapy and 20 diagnosed as new
TB cases). Twenty-two of these patients had been diagnosed
with TB based on positive smear microscopy while one
patient had negative microscopy result but positive chest
X-ray (Table 1). All the 23 study patients had a positive
culture. Based on morphological growths on Middlebrook
7H11 agar culture plates and the molecular analyses, we
identified 11/23 patients (48%) with MTC only, 9/23 (39%)
with NTM only, and 3/23 (13%) with evidence of both
MTC and NTM bacteria present (Table 1). The strains of
MTC identified through the spoligotyping represented Latin
America Mediterranean (LAM) genotype (𝑛 = 12), M.
africanum (𝑛 = 1), and the genotype family T (𝑛 = 1)
(Table 2). Using the INNO-LiPA identification assay, four
M. avium-intracellulare-M. scrofulaceum complexes, one M.
chelonae complex, oneM. abscessus, and oneM. intracellulare
were identified (Table 1). Seven NTM strains identified by
colony morphology on Middlebrook 7H11 solid media were
unavailable for the INNO-LiPA assay. In all, we identified 28
strains of Mycobacteria (i.e., both M. tuberculosis complex
and NTM) from the 23 patients screened.
In this study, NTM was identified in 50% (14/28) of
mycobacterial isolates recovered from the 23 patients diag-
nosed with TB at DOTS centers in Ibadan. Critically, using
culture, onlyNTMwas recovered from40% (8/20) of patients
diagnosed as new TB cases and in 33% (1/3) of patients
diagnosed as relapsed TB (i.e., among new patients, 40%
of them had only NTM without mixed infection with M.
tuberculosis and among relapse patients only one of them
had single infection with NTM without coinfection with M.
tuberculosis). This is an important finding since the potential
public health implications of TB misdiagnosis in patients
infected with NTM only are far-reaching. Invariably, these
patients are treated with anti-TB drugs including scarce and
more costly second line drugs in those with presumed relapse
and multidrug-resistant tuberculosis (MDR-TB). Associated
toxicities such as isoniazid hepatotoxicity may be life-
threatening while symptomatic NTM remains untreated. An
essential component of NTM treatment (macrolide) is not
included in any TB regimen. In addition, the public health
estimates of TB and MDR-TB are correspondingly distorted
by thesemisdiagnoses coupledwith unnecessary expenditure
of healthcare resources [6].
The findings of this study should be interpreted in the
context of its limitations which include evaluation of only
a single sputum sample from each patient [3, 7]. Repeated
isolation of the same NTM would have provided more defi-
nite evidence of true NTM infections. Risk factors associated
with NTM pulmonary disease were not assessed compre-
hensively due to limited clinical evaluations at the DOTS
centers. Specifically, information on HIV serological status
was available in only aminority of patients; however the 2008
prevalence data for the study area was only 2.2% [10]. This is
relevant sinceHIV affects the clinicalmanifestation of TB and
can increase pulmonary colonization with NTM [6]. Finally,
therewas nonavailability of sevenNTM isolates formolecular
characterization using the INNO-LiPA assay.
4. Conclusions
Despite the limitations of our findings, this study indicates
the possibility of erroneous TB diagnosis and treatment in
patients infected with NTM in our population. Ongoing
studies such as the national MDR-TB survey will shed
more light on the scope of this problem in Nigeria. Our
findings underscore an urgent need to incorporate molecular
techniques for more precise diagnosis of TB at DOTS centers
to improve clinical outcomes and safeguard public health,
particularly in TB endemic countries.
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